{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:35:13Z","timestamp":1775687713634,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Treatment patterns and healthcare resource utilization (HCRU) data in patients with locally advanced (stage III to IVB) squamous cell carcinoma of the head and neck (LA SCCHN) in Japan are limited. This study describes the patient demographics and characteristics, treatment patterns, HCRU, and costs among Japanese patients with newly diagnosed LA SCCHN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This longitudinal, observational, retrospective study was conducted using real-world medical claims data from the Medical Data Vision Co., Ltd. database in Japan (1 January 2015\u201331 July 2022). Patients aged \u226518 years at the index date (first date of locally advanced head and neck cancer [HNC] diagnosis) and having a confirmed diagnosis of HNC during 01 January 2016\u201330 June 2021 in the oral cavity, larynx, hypopharynx, or oropharynx (based on ICD-10 diagnostic codes) were included. Baseline demographic and clinical characteristics were collected during the pre-index period. Treatment patterns, HCRU, and associated costs were reported during the post-index period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the included 6741 patients with LA SCCHN, 51.3% received definitive nonsurgical treatment, 32.4% underwent primary resection, and 16.1% did not receive any agent. The most common chemotherapy agent used for chemoradiotherapy was cisplatin (74.7%). Docetaxel, cisplatin, and 5-fluorouracil combination (TPF) was used as induction chemotherapy for 28.6% of patients who received induction treatment followed by surgery and in 55.6% of patients who received induction treatment followed by radiotherapy. Patients receiving primary resection were typically older than those receiving definitive nonsurgical treatment for each cancer site and stage. Almost all patients had \u22651 all-cause hospitalizations with substantial HCRU-associated costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This real-world study demonstrates that treatment of patients with LA SCCHN in Japan often included definitive nonsurgical treatment or primary surgery. The substantial burden related to LA SCCHN-associated HCRU and considerable percentage of patients receiving no treatment highlights a need for novel and effective therapies for LA SCCHN.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1607280","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:02:17Z","timestamp":1756987337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment patterns, outcomes, healthcare resource utilization, and costs associated with locally advanced squamous cell carcinoma of the head and neck in Japan"],"prefix":"10.3389","volume":"15","author":[{"given":"Kenichi","family":"Nibu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramzi","family":"Argoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rascon-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makan","family":"Rahshenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bobiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ember","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.pathol.4.110807.092158","article-title":"Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment","volume":"4","author":"Pai","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu265","article-title":"The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck","volume":"25","author":"Psyrri","year":"2014","journal-title":"Ann Oncol"},{"key":"B4","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers\n          \n          \n          \n          2024"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coms.2014.01.001","article-title":"Epidemiological trends in head and neck cancer and aids in diagnosis","volume":"26","author":"Vigneswaran","year":"2014","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B7","unstructured":"Projected cancer statistics\n          \n          \n          \n          2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4539","article-title":"Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan","volume":"11","author":"Kawakita","year":"2022","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104551","article-title":"Global patterns and trends in cancers of the lip, tongue and mouth","volume":"102","author":"Miranda-Filho","year":"2020","journal-title":"Oral Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41415-022-5166-x","article-title":"Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors","volume":"233","author":"Gormley","year":"2022","journal-title":"Br Dent J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100309","article-title":"Pan-Asian adaptation of the EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck","volume":"6","author":"Keam","year":"2021","journal-title":"ESMO Open"},{"key":"B12","unstructured":"Laryngeal and hypopharyngeal Cancer Causes, Risk Factors, and Prevention\n          \n          \n          \n          2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000629","article-title":"Epidemiology of head and neck cancers: An update","volume":"32","author":"Aup\u00e9rin","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm233","article-title":"Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer","volume":"99","author":"Applebaum","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0347","article-title":"Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the INHANCE consortium","volume":"18","author":"Hashibe","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","first-page":"FSO347","DOI":"10.4155\/fsoa-2018-0058","article-title":"Genetics and management of locally advanced carcinomas of the head and neck: Role of altered fractionation radiotherapy","volume":"5","author":"Perri","year":"2018","journal-title":"Futur Sci OA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3290\/j.cjdr.a33965","article-title":"An overview of detection and screening of oral cancer in Taiwan","volume":"18","author":"Kao","year":"2015","journal-title":"Chin J Dent Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10989-021-10334-5","article-title":"Head and neck squamous cell carcinoma: risk factors, molecular alterations, immunology and peptide vaccines","volume":"28","author":"Sun","year":"2022","journal-title":"Int J Pept Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01835-2","article-title":"Treating head and neck cancer in the age of immunotherapy: A 2023 update","volume":"83","author":"Bhatia","year":"2023","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00199","article-title":"Treatment of elderly patients with squamous cell carcinoma of the head and neck","volume":"6","author":"Szturz","year":"2016","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01742-6","article-title":"Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil","volume":"25","author":"Shirasu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13601","article-title":"Predictive factors for completion of TPF induction chemotherapy in patients with locally advanced head and neck cancer","volume":"39","author":"Nakano","year":"2019","journal-title":"Anticancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113427","article-title":"Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: A retrospective multicenter study of 88 patients","volume":"12","author":"Matsuki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15948","article-title":"Real-world therapeutic outcomes of the pembrolizumab regimen as first-line therapy for recurrent\/metastatic squamous cell carcinoma of the head and neck: A single-center retrospective cohort study in Japan","volume":"42","author":"Sano","year":"2022","journal-title":"Anticancer Res"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2","article-title":"NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse","volume":"43","author":"Bourhis","year":"2025","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2025-CT001","article-title":"Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study","volume":"85","author":"Uppaluri","year":"2025","journal-title":"Cancer Res"},{"key":"B28","unstructured":"Report of head and neck Cancer Registry of Japan Clinical Statistics of Registered Patients\n          \n          \n          2019"},{"key":"B29","unstructured":""},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.04.010","article-title":"Systemic treatment patterns with advanced or recurrent non\u2013small cell lung cancer in Japan: A retrospective hospital administrative database study","volume":"39","author":"Wang","year":"2017","journal-title":"Clin Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1927691","article-title":"Healthcare resource utilization and economic burden of antifungal management in patients with hematologic Malignancy in Japan: a retrospective database study","volume":"37","author":"Ueno","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5069","article-title":"An association between cancer type and delirium incidence in Japanese elderly patients: A retrospective longitudinal study","volume":"12","author":"Yamato","year":"2023","journal-title":"Cancer Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.36469\/JHEOR.2020.12853","article-title":"Re-challenge of platinum-based chemotherapy for platinum-refractory patients with recurrent or metastatic head and neck cancer: Claims data analysis in Japan","volume":"7","author":"Tahara","year":"2020","journal-title":"J Heal Econ Outcomes Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data","volume":"47","author":"Van Walraven","year":"2016","journal-title":"Med Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2022.3269","article-title":"Quantifying total and out-of-pocket costs associated with head and neck cancer survivorship","volume":"148","author":"Massa","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07297-z","article-title":"Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: A nationwide retrospective cohort study (KCSG HN13-01)","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1016\/j.jval.2023.03.2086","article-title":"RWD57 real-world treatment patterns of elderly patients with locally advanced squamous cell carcinoma of the head and neck in the US","volume":"26","author":"Lu","year":"2023","journal-title":"Value Heal"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5935\/1808-8694.20130041","article-title":"Head and neck cancer: Causes, prevention and treatment","volume":"79","author":"Galbiatti","year":"2013","journal-title":"Braz J Otorhinolaryngol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S115761","article-title":"Head and neck cancer: Improving outcomes with a multidisciplinary approach","volume":"9","author":"Lo Nigro","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B41","article-title":"OVERVIEW: HEAD & NECK","volume-title":"Localization & Treatment Procedures in Radiation Therapy","author":"Stiles","year":"2023"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4143\/CRT.2020.1329","article-title":"Induction chemotherapy as a prognostication index and guidance for treatment of locally advanced head and neck squamous cell carcinoma: the concept of chemo-selection (KCSG HN13-01)","volume":"54","author":"Lee","year":"2022","journal-title":"Cancer Res Treat"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyx115","article-title":"Chemo-selection with docetaxel, cisplatin and 5-fluorouracil (TPF) regimen followed by radiation therapy or surgery for pharyngeal and laryngeal carcinoma","volume":"47","author":"Matoba","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.25107\/2474-1663-v4-id1657","article-title":"Feasibility of combination of paclitaxel, carboplatin, and cetuximab as induction chemotherapy for advanced head and neck squamous cell carcinoma","volume":"4","author":"Takenaka","year":"2019","journal-title":"Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2852","article-title":"A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck","volume":"9","author":"Enokida","year":"2020","journal-title":"Cancer Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/cancers15030672","article-title":"Integrating immunotherapy into multimodal treatment of head and neck cancer","volume":"15","author":"Rao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608772","article-title":"Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges","volume":"10","author":"Qian","year":"2021","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa139","article-title":"Immunotherapy for squamous cell carcinoma of the head and neck","volume":"50","author":"Yokota","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101426","article-title":"Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials","volume":"21","author":"Goel","year":"2022","journal-title":"Transl Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0169-3","article-title":"The economic burden of head and neck cancer: A systematic literature review","volume":"32","author":"Wissinger","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.130.11.1269","article-title":"The economic cost of squamous cell cancer of the head and neck","volume":"130","author":"Lang","year":"2004","journal-title":"Arch Otolaryngol Neck Surg"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.0940","article-title":"Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers","volume":"141","author":"Hollenbeak","year":"2015","journal-title":"JAMA Otolaryngol - Head Neck Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1607280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:02:20Z","timestamp":1756987340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1607280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":52,"alternative-id":["10.3389\/fonc.2025.1607280"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1607280","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1607280"}}